Table 2 Tier 2 results of low, medium and high-risk drug and patient variables for developing pneumotoxicity based on median values. RA: rheumatoid arthritis, SSc: systemic sclerosis, SLE: systemic lupus erythematosus, MCTD: mixed connective tissue disease
Low risk | Medium risk | High risk | |
|---|---|---|---|
Drug | Sulphasalazine | Leflunomide | |
Tocilizumab | Adalimumab | ||
Baricitinib | Certolizumab | ||
Abatacept | Etanercept | ||
Tofacitinib | Golimumab | ||
Infliximab | |||
Anakinra | |||
Ustekinumab | |||
Rituximab | |||
Methotrexate | |||
Age (years) | < 49 | 50–69 | ≥ 70 |
Smoking | never | ex | current |
Connective tissue disease | Psoriatic arthropathy, Ankylosing spondylitis | RA, SSc, SLE, Primary Sjogren's, MCTD, Anti-synthetase syndromes, systemic vasculitis, sarcoidosis | |
Connective tissue disease activity | Low | Medium | High |
Cardiac comorbidities | Nil or presence of coronary artery disease | Left ventricular failure Cor pulmonale, Pulmonary hypertension | |
Renal comorbidities: estimated glomerular filtration rate | ≥ 60 | < 60 | |
Previous pneumotoxicity | NO | YES |